NCT04301310View on ClinicalTrials.gov

Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 9, 2020

Primary Completion Date

March 16, 2020

Study Completion Date

March 16, 2020

Conditions
Healthy Participants
Interventions
DRUG

BMS-986235 (Treatment A)

Specified dose on specified days

DRUG

Rifampin (Treatment B)

Specified dose on specified days

Trial Locations (1)

84124

Local Institution, Salt Lake City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY